FDA Inspection 1313526 — Summit Rx Inc
The FDA completed an inspection of Summit Rx Inc on April 23, 2026 in Bayonne, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Food/Cosmetics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- April 23, 2026
- Fiscal Year
- 2026
- Product Type
- Food/Cosmetics
- Project Area
- Food Composition, Standards, Labeling and Econ
- Location
- Bayonne, NJ (United States)
Citations
| ID | CFR | Description |
|---|---|---|
| 15702 | 21 CFR 111.320(b) | Examination, testing; scientifically valid |